Related Experiment Video

Updated: Mar 2, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Prevention of Stroke in Patients With Atrial Fibrillation

Talal Moukabary1, Gerald V Naccarelli1

  • 1Electrophysiology Program Heart and Vascular Institute, Penn State University College of Medicine Hershey, Pennsylvania, USA.

Journal of Atrial Fibrillation
|May 13, 2017
PubMed

Insights

Atrial fibrillation (AF) increases stroke risk. Novel anticoagulants like dabigatran, rivaroxaban, and apixaban offer effective stroke prevention for AF patients, reducing intracranial hemorrhage risk without INR monitoring.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) significantly elevates stroke risk, particularly in individuals with identified risk factors (CHADS2, CHA2DS2-VASc scores).
  • Warfarin, a traditional anticoagulant, reduces stroke rates by over 65% but has low adherence (55% in the USA) due to monitoring and interaction challenges.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation.
  • To compare the benefits of NOACs against traditional anticoagulation in managing AF-related stroke risk.

Main Methods:

  • Review of large-scale clinical trials investigating the efficacy of dabigatran (direct thrombin inhibitor), rivaroxaban, and apixaban (Factor Xa inhibitors).
  • Analysis of stroke reduction rates, intracranial hemorrhage risk, and patient adherence factors associated with NOACs versus warfarin.

Main Results:

  • Dabigatran, rivaroxaban, and apixaban have demonstrated significant efficacy in reducing stroke incidence in patients with AF.
  • These novel agents offer stroke prevention with a lower risk of intracranial hemorrhage compared to warfarin.
  • NOACs eliminate the need for regular INR monitoring and have fewer drug-dietary interactions.

Conclusions:

  • Novel oral anticoagulants represent a significant advancement in stroke prevention for atrial fibrillation patients.
  • NOACs provide a more convenient and potentially safer alternative to warfarin, improving patient adherence and outcomes.
  • The therapeutic landscape for AF management is shifting towards NOACs due to improved safety and usability profiles.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K

Related Concept Videos

Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
532
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
426
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
776
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
547
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K